PMID- 2253244
OWN - NLM
STAT- MEDLINE
DCOM- 19910123
LR  - 20201222
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 50
IP  - 24
DP  - 1990 Dec 15
TI  - Characterization of the epidermal growth factor receptor in human glioma cell 
      lines and xenografts.
PG  - 8017-22
AB  - Both permanent cultured cell lines and athymic mouse xenografts were established 
      from two human glioblastomas. Biopsies from D-245 MG and D-270 MG contained 
      amplified and rearranged epidermal growth factor receptor (EGFR) genes. Although 
      the gene amplification and rearrangement seen originally was maintained in the 
      xenografts, cultured cell lines established from these biopsies lost the 
      amplified rearranged genes in vitro. Analysis of these cell lines and 11 
      additional permanent human glioma cell lines with normal EGFR gene copy number 
      showed from 2.7 x 10(3) to 4.1 x 10(5) high affinity EGFRs/cell by radioreceptor 
      assay. The RNase A protection assay showed minimal differences in the quantity of 
      EGFR mRNA among the 13 glioma lines, while the D-245 MG and D-270 MG xenografts 
      expressed approximately 10-20 times as much EGFR mRNA as the corresponding cell 
      lines. Immunoprecipitation of EGFR from these lines, including D-245 MG and D-270 
      MG, demonstrated only the intact Mr 170,000 Da form, while truncated Mr 145,000 
      Da and 100,000 Da EGFR proteins were immunoprecipitated from the D-270 MG and 
      D-245 MG xenografts, respectively. These studies demonstrate that gliomas with 
      amplification of the EGFR gene are capable of establishing in culture but that 
      the amplified rearranged genes are not maintained. Possible explanations are that 
      the abnormal genes are lost during serial passage or that the cells with 
      amplified rearranged genes only represent a minor subpopulation of cells, which 
      are unable to grow in culture. In either case, these observations suggest that 
      high expression and structural abnormalities of EGFR proteins generated by 
      amplification and rearrangement of the EGFR gene provide a growth advantage for 
      gliomas in vivo but not in vitro.
FAU - Bigner, S H
AU  - Bigner SH
AD  - Department of Pathology, Duke University Medical Center, Durham, North Carolina 
      27710.
FAU - Humphrey, P A
AU  - Humphrey PA
FAU - Wong, A J
AU  - Wong AJ
FAU - Vogelstein, B
AU  - Vogelstein B
FAU - Mark, J
AU  - Mark J
FAU - Friedman, H S
AU  - Friedman HS
FAU - Bigner, D D
AU  - Bigner DD
LA  - eng
GR  - CA-11898/CA/NCI NIH HHS/United States
GR  - CA-43460/CA/NCI NIH HHS/United States
GR  - CA-44640/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (DNA, Neoplasm)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Cell Line
MH  - Chromosome Mapping
MH  - DNA, Neoplasm/genetics/isolation & purification
MH  - Epidermal Growth Factor/metabolism
MH  - ErbB Receptors/*genetics
MH  - Gene Amplification
MH  - Glioma/*genetics/metabolism
MH  - Humans
MH  - Karyotyping
MH  - Kinetics
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Nucleic Acid Hybridization
MH  - Transplantation, Heterologous
EDAT- 1990/12/15 00:00
MHDA- 1990/12/15 00:01
CRDT- 1990/12/15 00:00
PHST- 1990/12/15 00:00 [pubmed]
PHST- 1990/12/15 00:01 [medline]
PHST- 1990/12/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1990 Dec 15;50(24):8017-22.